Fifteen Years of Experience with Intrathecal Autologous Bone Marrow–Derived Cells: Safety, Infection Profile, and Caregiver-Reported Outcomes in CP and ASD

Key Points

• Favorable caregiver-reported outcomes were observed over 15 years for participants receiving intrathecal autologous bone marrow-derived cells.
• The infection profile indicated a low incidence of complications, enhancing the safety profile of the intervention.
• Observational analysis revealed that patients with CP and ASD benefited from these treatments, with caregivers noting improved outcomes.
• These findings support potential wider application of intrathecal autologous bone marrow-derived cells, but further studies are warranted.